#Corona Vaccine

Current COVID strain mild, SII has produced five to six million Covovax doses: Adar Poonawalla
#Corona Vaccine

Who was Andrey Botikov? Russian top scientist behind Sputnik V Covid vaccine found dead
#Corona Vaccine

World's first nasal vaccine for Covid-19 iNCOVACC launched on Republic Day
#Corona Vaccine

Union Minister Jitendra Singh lauds team Biotech for world’s first Nasal Covid vaccine
#Corona Vaccine

India's first intranasal Covid vaccine to be launched on Republic Day
#Corona Vaccine

How Pfizer tried to bully India to buy its 'ineffective' Covid vaccine

Adar Poonawalla urges countries please be patient for supplies, Serum directed to prioritise India needs

| Updated: Sunday, February 21, 2021, 12:28 [IST]

New Delhi, Feb 21: Adar Poonawalla, CEO of vaccine major Serum Institute of India (SII), on Sunday urged other countries to be patient as they wait for the supplies of COVID-19 vaccine, Covishield, as the company has been directed to prioritise the needs of India.

Adar Poonawalla urges countries please be patient, Serum directed to prioritise India needs

Apart from making efforts to meet the requirements of India, the company is also trying its best to balance the needs of the rest of the world, he added.

Pfizer-BioNTech data shows vaccine easier to use Pfizer-BioNTech data shows vaccine easier to use

"Dear countries and governments, as you await #COVISHIELD supplies, I humbly request you to please be patient, @SerumInstIndia has been directed to prioritise the huge needs of India and along with that balance the needs of the rest of the world. We are trying our best", Poonawalla said in a tweet.

On February 15, the World Health Organisation (WHO) listed two versions of the AstraZeneca/Oxford COVID-19 vaccine for emergency use, giving the green light for these vaccines to be rolled out globally through COVAX. The vaccines are produced by AstraZeneca-SKBio (Republic of Korea) and the Serum Institute of India.